- Orthocell highlights potential for CelGro in treatment of lymphedema 1.075 Aufrufe03.08.2021
Orthocell Ltd's Paul Anderson speaks to Proactive after announcing a breakthrough tissue engineering study, combining CelGro® with lymphatic and blood vessel cells to create functional lymphatic tissue, has been published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS). The findings represent a substantial advance in the ex vivo fabrication of implantable lymphatic grafts and their use in novel surgical treatments for patients suffering from lymphedema. -
OCC Price at posting:
53.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)